申请人:Taisho Pharmaceutical Co., Ltd.
公开号:US05597921A1
公开(公告)日:1997-01-28
Indolo[2,3-b]quinoxaline derivatives represented by the following formula: ##STR1## wherein one of R.sup.1 and R.sup.2 is a hydrogen atom and the other is a group of the formula: --CH.sub.2 NHCCH.sub.3 (CH.sub.2 OH).sub.2, etc, and R.sup.3 is a hydrogen atom, a methyl group, etc.; and pharmaceutically acceptable salts thereof have an antitumor activity and are useful as medicines.
以下是Indolo[2,3-b]quinoxaline衍生物的化学式:##STR1## 其中R.sup.1和R.sup.2中的一个是氢原子,另一个是公式为:--CH.sub.2 NHCCH.sub.3 (CH.sub.2 OH).sub.2等的基团,R.sup.3是氢原子,甲基基团等;其药学上可接受的盐具有抗肿瘤活性,可用作药物。